Dr. John Sarantopoulos, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 29
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 314
Licensed in Texas since 2004, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license L8940 (first issued 2004; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University Health System San Antonio, TX
- Ut Health San Antonio Multispecialty & Research Ho San Antonio, TX
Medical groups
- University of Texas Health Science Center at San Antonio (1,297 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 314
- Services billed
- 52,593
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, oxaliplatin, 0.5 mg | 4,430 | 12 |
| Injection, pembrolizumab, 1 mg | 3,600 | 14 |
| Injection, fosaprepitant, 1 mg | 3,000 | 15 |
| Injection, ondansetron hydrochloride, per 1 mg | 768 | 36 |
| Injection, dexamethasone sodium phosphate, 1 mg | 689 | 41 |
| Injection, fluorouracil, 500 mg | 263 | 17 |
| Injection, palonosetron hcl, 25 mcg | 210 | 16 |
| Established patient office or other outpatient visit, 30-39 minutes | 208 | 107 |
| Injection, magnesium sulfate, per 500 mg | 160 | 19 |
| Injection of additional new drug or substance into vein | 155 | 51 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in San Antonio, TX | 102 |
| Prednisone Other prescribers in San Antonio, TX | 95 |
| Abiraterone Acetate | 88 |
| Cabometyx (cabozantinib s-malate) | 34 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in San Antonio, TX | 30 |
| Xtandi (enzalutamide) | 29 |
| Alprazolam Other prescribers in San Antonio, TX | 22 |
| Morphine Sulfate Other prescribers in San Antonio, TX | 21 |
| Ondansetron Hcl Other prescribers in San Antonio, TX | 20 |
| Dexamethasone Other prescribers in San Antonio, TX | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 67 payments worth $57,957 in total to this clinician.
| Pfizer Inc. | $33,685 |
|---|---|
| Exelixis Inc. | $17,135 |
| Regeneron Healthcare Solutions, Inc. | $6,231 |
| Array Biopharma Inc | $700 |
| Janssen Biotech, Inc. | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | $34.76 |
| Novartis Pharmaceuticals Corporation | $27.95 |
| Aveo Pharmaceuticals, Inc. | $15.00 |
| Compensation for services other than consulting (speaking, faculty) | $32,059 |
|---|---|
| Speaking at a medical education program | $14,685 |
| Travel and Lodging | $8,405 |
| Consulting Fee | $1,780 |
| Food and Beverage | $1,013 |
| Education | $15.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Exelixis Inc. Sep 24, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $5,940 |
| Pfizer Inc. Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $5,500 |
| Pfizer Inc. Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $5,125 |
| Pfizer Inc. Apr 28, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $5,125 |
| Pfizer Inc. Jun 16, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $5,125 |
| Pfizer Inc. Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $5,125 |
| Regeneron Healthcare Solutions, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $4,902 |
| Exelixis Inc. Mar 26, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $4,455 |
| Exelixis Inc. Aug 12, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,980 |
| Exelixis Inc. Aug 19, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,980 |
All 50 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Aveo Pharmaceuticals, Inc. Nov 6, 2025 | Education FOTIVDA · Oncology · in-kind | $15.00 |
| Regeneron Healthcare Solutions, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $4,902 |
| Regeneron Healthcare Solutions, Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $1,157 |
| Pfizer Inc. Oct 16, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Rosemont, IL · in-kind | $784 |
| Pfizer Inc. Oct 15, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Rosemont, IL · in-kind | $197 |
| Exelixis Inc. Sep 24, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $5,940 |
| Exelixis Inc. Sep 13, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind | $211 |
| Exelixis Inc. Sep 13, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind | $70.00 |
| Exelixis Inc. Sep 13, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind | $70.00 |
| Exelixis Inc. Sep 13, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL | $27.99 |
| Pfizer Inc. Aug 20, 2025 | Consulting Fee PADCEV · ONCOLOGY | $1,080 |
| Exelixis Inc. Aug 19, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,980 |
| Exelixis Inc. Aug 12, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,980 |
| Pfizer Inc. Aug 1, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Kildeer, IL · in-kind | $636 |
| Exelixis Inc. Jul 18, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind | $281 |
| Exelixis Inc. Jul 10, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $330 |
| Pfizer Inc. Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $5,500 |
| Pfizer Inc. Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $5,125 |
| Pfizer Inc. Jun 25, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Oklahoma City, OK · in-kind | $452 |
| Pfizer Inc. Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $5,125 |
| Pfizer Inc. Jun 24, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Kildeer, IL · in-kind | $159 |
| Pfizer Inc. Jun 21, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Kildeer, IL · in-kind | $224 |
| Pfizer Inc. Jun 19, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Dallas, TX · in-kind | $14.13 |
| Pfizer Inc. Jun 18, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Oklahoma City, OK · in-kind | $685 |
| Pfizer Inc. Jun 16, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $5,125 |
| Pfizer Inc. Jun 16, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Oklahoma City, OK · in-kind | $200 |
| Pfizer Inc. Jun 16, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Oklahoma City, OK · in-kind | $35.00 |
| Pfizer Inc. Jun 16, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Oklahoma City, OK · in-kind | $18.99 |
| Pfizer Inc. Jun 10, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Kildeer, IL · in-kind | $645 |
| Pfizer Inc. Jun 10, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Oklahoma City, OK · in-kind | $207 |
| Pfizer Inc. Jun 7, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Oklahoma City, OK · in-kind | $435 |
| Pfizer Inc. Apr 29, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Columbia, MO · in-kind | $140 |
| Pfizer Inc. Apr 29, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Columbia, MO · in-kind | $34.99 |
| Pfizer Inc. Apr 28, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $5,125 |
| Pfizer Inc. Apr 26, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Columbia, MO · in-kind | $266 |
| Pfizer Inc. Apr 22, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Columbia, MO · in-kind | $207 |
| Pfizer Inc. Apr 15, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Columbia, MO · in-kind | $664 |
| Exelixis Inc. Mar 26, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $4,455 |
| Exelixis Inc. Mar 24, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO · in-kind | $369 |
| Exelixis Inc. Mar 21, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO | $34.99 |
| Exelixis Inc. Mar 20, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO · in-kind | $394 |
| Exelixis Inc. Mar 20, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO · in-kind | $70.00 |
| Exelixis Inc. Mar 12, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO · in-kind | $357 |
| Exelixis Inc. Mar 12, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO · in-kind | $234 |
| Exelixis Inc. Mar 12, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO · in-kind | $70.00 |
| Exelixis Inc. Mar 12, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO · in-kind | $70.00 |
| Exelixis Inc. Mar 12, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO · in-kind | $69.99 |
| Exelixis Inc. Mar 12, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Denver, CO · in-kind | $37.79 |
| Array Biopharma Inc Mar 6, 2025 | Consulting Fee BRAFTOVI · ONCOLOGY | $700 |
| Regeneron Healthcare Solutions, Inc. Feb 4, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to TARRYTOWN, NY · in-kind | $32.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $3,846,455 in research payments for these studies, mostly to the institutions running them.
- A Phase 1a,1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 as a Single Agent and in Combination with Pembrolizumab i…
Merck Sharp & Dohme LLC - An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals Corporation - A Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120, as a Single agent and in Combination with Pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors
Merck Sharp & Dohme LLC - Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy
Gilead Sciences, Inc. - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.